99% FDA-Approved Bacitracin API Of GMP/CEP Factory In China

Topical Antibiotic Preparations

Bacitracin is widely used in topical formulations to prevent and treat localized skin infections. First-aid antibiotic ointments containing Bacitracin (often in combination with neomycin and polymyxin B) are used to help prevent infection in minor cuts, burns, and scrapes. Its efficacy against common Gram-positive pathogens, including Staphylococci そして Streptococci, makes it a trusted component of over-the-counter and prescription topical antibiotic products.

Ophthalmic Applications

Bacitracin is indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin-susceptible organisms. It is formulated as a sterile ophthalmic ointment, often in combination with polymyxin B sulfate. Ophthalmic preparations containing Bacitracin are used for:

• Superficial bacterial infections of the external eye and its adnexa

• Corticosteroid-responsive ocular conditions with concurrent superficial bacterial infection or risk of infection

注射剤

Bacitracin for Injection, USP, is a sterile preparation for intramuscular administration. It is used for systemic antibiotic therapy in serious infections caused by susceptible organisms. A dose of 200–300 units/kg every 6 hours achieves serum levels of 0.2 to 2 mcg/mL in individuals with normal renal function. Bacitracin for Injection is typically administered only in hospital settings due to its nephrotoxicity profile.

調剤薬局アプリケーション

For compounding pharmacies, our Bacitracin API provides the flexibility to formulate:

• Topical ointments and creams — for wound care and skin infections

• Ophthalmic ointments — for ocular infections

• Custom combination products — with neomycin, polymyxin B, or corticosteroids

• Specialized preparations — for patients with sensitivities to other antibiotics

Bacitracin for prescription compounding is the purified, dried form intended for extemporaneous compounding by practicing pharmacists. For prescription compounding use, the label should indicate that it is not sterile and that the potency cannot be assured for longer than 60 days after opening — a critical consideration for compounding pharmacists managing beyond-use dating.